Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria

Figure 1

Clinical course of the patient. On February 12, 2008, he was enrolled in the AEGIS clinical trial. (a) Administration of eculizumab resulted in a rapid reduction of LDH. Asterisk indicates the increased LDH due to delayed administration of eculizumab during an AE of hyperbilirubinemia. Arrow indicates eculizumab treatment. (b) He was complicated with stage 3 CKD, grade G3b, and obvious proteinuria, at baseline. Eculizumab treatment improved eGFR gradually. Since two years after introduction of eculizumab, eGFR at grade G2 and no proteinuria have been maintained. Closed squares denote grades of proteinuria (−, ±, +, 2+, and 3+).

(a)

(b)